Patents by Inventor Bo-Eun Yoon

Bo-Eun Yoon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ATTENTION DEFICIT/HYPERACTIVITY DISORDER, CONTAINING KDS2010 AS ACTIVE INGREDIENT
    Publication number: 20240423932
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating attention deficit/hyperactivity disorder (ADHD), containing KDS2010 as an active ingredient, wherein it has been identified, in a Git1 gene-deficient hetero (+/?) mouse, that the amount of GABA is increased in the striatum of the brain, which is in charge of hyperactivity, and thus the mouse can be used as an animal model of ADHD, and it has been identified that inattention and hyperactivity are alleviated upon the administration of KDS2010 to the Git1 gene-deficient hetero (+/?) mouse, and thus KDS2010 is provided as an agent for treating ADHD.
    Type: Application
    Filed: August 19, 2021
    Publication date: December 26, 2024
    Applicant: DANKOOK UNIVERSITY CHEONAN CAMPUS INDUSTRY ACADEMIC COOPERATION FOUNDATION
    Inventors: Bo-Eun Yoon, Ki Duk Park, Jong-Hyun Park
  • PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ATTENTION DEFICIT/HYPERACTIVITY DISORDER
    Publication number: 20240350471
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating attention deficit/hyperactivity disorder (ADHD), including SNAP5114 as an active ingredient. A Git1 gene-deficient hetero (+/?) mouse, confirmed to have increased amount of GABA in the brain striatum that controls hyperactivity, can be used as an animal model of ADHD, and by confirming that hyperactivity is ameliorated by administering SNAP5114 to the Git1 gene-deficient hetero (+/?) mouse, SNAP5114 is provided as a therapeutic agent for ADHD.
    Type: Application
    Filed: August 20, 2021
    Publication date: October 24, 2024
    Applicants: DANKOOK UNIVERSITY CHEONAN CAMPUS INDUSTRY ACADEMIC COOPERATION FOUNDATION, INSTITUTE FOR BASIC SCIENCE
    Inventors: Bo-Eun Yoon, C. Justin Lee, Yoo Sung Kim, Moonsun Sa
  • GABA release-regulating agent in cerebellum
    Patent number: 9095535
    Abstract: A GABA (gamma-aminobutyric acid) release-inhibiting agent in the cerebellum and a composition for treating pathological symptoms caused by over-release of GABA in the cerebellum, each comprising a Bestrophin 1 (Best1) channel inhibitor as an active ingredient; a GABA release-promoting agent in the cerebellum and a composition for treating pathological symptoms caused by the deficit of GABA in the cerebellum, each comprising a Best1 channel activator as an active ingredient; and a method for screening a GABA release-regulating agent in the cerebellum, which uses Best1 channel as target, are provided.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: August 4, 2015
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Changjoon Justin Lee, Soo-Jung Lee, Bo-Eun Yoon
  • GABA RELEASE-REGULATING AGENT IN CEREBELLUM
    Publication number: 20120214742
    Abstract: A GABA (gamma-aminobutyric acid) release-inhibiting agent in the cerebellum and a composition for treating pathological symptoms caused by over-release of GABA in the cerebellum, each comprising a Bestrophin 1(Best1) channel inhibitor as an active ingredient; a GABA release-promoting agent in the cerebellum and a composition for treating pathological symptoms caused by the deficit of GABA in the cerebellum, each comprising a Best1 channel activator as an active ingredient; and a method for screening a GABA release-regulating agent in the cerebellum, which uses Best1 channel as target, are provided.
    Type: Application
    Filed: August 24, 2010
    Publication date: August 23, 2012
    Inventors: Changjoon Justin Lee, Soo-Jung Lee, Bo-Eun Yoon